Matured Hop Bitter Acids (MHBA): Cognitive Function, Attention, and Human Evidence

Matured Hop Bitter Acids (MHBA) are among the more interesting ingredients used in Japan’s foods with cognitive-function claims. The human evidence is stronger than it is for many common supplement ingredients, but it remains far below the standard expected for a drug.

The most promising findings concern attention, information processing, and executive control—not a blanket improvement in every type of memory. MHBA may influence cognition through the vagus nerve–norepinephrine system. A separate body of human research also suggests a modest reduction in visceral fat.

1. What Are Matured Hop Bitter Acids?

The Japanese term is:

熟成ホップ由来苦味酸

The English name is:

Matured Hop Bitter Acids Abbreviated as:

MHBA / MHBAs

The most important point is:

It is not a separate chemical molecule.

MHBA is a mixture of oxidized bitter acids formed as hop bitter acids age and oxidize during storage.

Hops primarily contain:

α-acids and β-acids

Among them, α-acids isomerize during the boiling process of normal beer brewing into the famous:

iso-α-acids (iso-alpha acids)

These things make up a large part of the bitterness of traditional beer.

MHBA, by contrast, consists mainly of compounds created through the oxidation and maturation of hop bitter acids. Chemical analyses indicate that its principal constituents are α-acid-derived oxides with a shared β-tricarbonyl structural feature.

So:

ordinary hops ≠ MHBA

regular beer ≠ MHBA supplement

iso-α-acids ≠ MHBA

The three should not be confused.

2. What Does MHBA Contain?

MHBAs are essentially a whole “family of bitter acid oxides.”

Representative ingredients identified in the study include such as:

4′-hydroxyallohumulinones（HAH）

and:

4′-hydroxyalloisohumulones / HAIH

Oxidized derivatives.

Researchers even isolated and tested HAH and HAIH in animal experiments and found that they can also reproduce part of the neurophysiological effects of MHBA, which shows that it is not just "anything in hop extract is effective."

This is actually better than many plant extracts:

Many health products simply say:

"Contains 500 mg of a certain plant extract"

It’s not clear what’s inside.

MHBA has at least established a relatively systematic chemical analysis method and knows a number of major active structures.

3. What Effects Are Most Plausible?

Using human evidence as the priority rather than animal findings, the current signals can be summarized as follows:

The most relevant human trials are outlined below.

4. Human RCT 1: 60 Participants, 35 mg/day for 12 Weeks

The first study, published in 2020, was a:

randomized, double-blind, placebo-controlled trial.

Participants:

60 healthy adults

Age:

45–64 years

Eligibility:

Participants reported some degree of subjective cognitive decline, such as feeling that concentration or memory was not as good as it used to be.

Daily dose:

MHBA 35 mg/day

Duration:

12 weeks

Cognitive and mental status tests were conducted at baseline, weeks 6, and 12.

5. Result 1: Verbal Fluency

At week 6:

Verbal Fluency Test

Participants must produce as many words as possible within a fixed time while following a specified rule.

The MHBA group showed greater improvement than the placebo group:

p = 0.034

The difference was statistically significant.

This test actually doesn't just test "how many words you know."

It requires:

rapid memory search → suppressing repeated answers → sustained attention → applying a strategy → rapid information retrieval

So it relies more on:

frontal/executive function

That is, prefrontal lobe related functions.

6. Result 2: Stroop Test

After 12 weeks:

Stroop test

The MHBA group performed significantly better than placebo:

p = 0.019

The Stroop is a very classic test of executive control.

Take a classic example:

Red

But the word "red" is actually written in blue font.

The task asks:

What color is the font?

People’s automatic response is often to read:

red

But the correct answer is:

blue

Therefore it is necessary to:

suppressing an automatic response + maintaining the task goal + selecting the correct information + ignoring interference

So what it tests is:

inhibitory control

selective attention

executive control

This also means:

Human evidence for MHBA favors “attentional control”

Rather than a "memory enhancer" in the traditional sense.

7. Mental Fatigue and Anxiety

After 12 weeks in this study:

subjective fatigue

MHBA outperformed placebo:

p = 0.008

Anxiety results:

anxiety

Anxiety scores also improved:

p = 0.043.

So the overall picture given by the study is:

Attention/executive control improved a bit + mental fatigue dropped a bit + anxiety dropped a bit.

This is very consistent with the "vagus nerve-autonomic nervous system" mechanism discovered later by MHBA.

But it needs to be clear:

It cannot be called an "anti-anxiety drug" for this reason.

These are just changes in a questionnaire in healthy adults, not a treatment trial in people with anxiety disorders.

8. A Second, Larger Cognitive RCT: 100 Participants

A second randomized, double-blind, placebo-controlled trial published in 2020 enrolled a larger sample.

Participants:

100 people

Age:

45–69 years

All had:

self-reported cognitive decline

subjective cognitive decline

Randomization:

placebo 50 and MHBA 50

Duration:

12 weeks

The intervention again used an MHBA supplement.

The core dose remained:

35 mg/day

It can be seen from this:

35 mg/day

This is the principal standard dose used in human MHBA studies.

9. Key Result: SDMT

After 12 weeks:

Symbol Digit Modalities Test

SDMT

The MHBA group was significantly better than placebo:

p = 0.045

The SDMT is a very interesting cognitive test.

In simple terms, the screen or test sheet first presents a key:

It pairs each:

symbol ↔ number

Participants then use those pairings to match new symbols with the correct numbers.

New symbols then appeared continuously, and subjects needed to quickly find the corresponding numbers.

The task draws on:

visual scanning + sustained attention + divided attention + processing speed + working memory

Researchers mainly explain it as:

divided attention

distributed attention

The reported improvement was therefore interpreted mainly as a change in divided attention.

10. Why This Result Needs Cautious Interpretation

The p-value is:

0.045

Statistical significance is usually expressed as:

p < 0.05

as the conventional threshold.

In other words:

It just crosses the line of statistical significance.

In addition, the study tested not just one item of SDMT, but multiple cognitive, emotional and biomarker indicators.

So the best statement this study demonstrates is not:

“35 mg of MHBA significantly enhances cognitive performance.”

Instead:

In a series of tests, MHBA showed positive signals for some indicators such as distributed attention.

This is very important.

11. Did Memory Improve?

There is an interesting result, but the level of evidence is a bit lower.

The researchers conducted an additional analysis of:

people who clearly felt that their cognition had declined, but not to the point of requiring medical intervention.

This subgroup was analyzed separately.

In this subgroup:

verbal paired-associate learning

and:

Rey Auditory Verbal Learning Test

Measures of memory retrieval in these tests improved more with MHBA than with placebo.

So MHBA is not completely useless for memory.

However:

This is subgroup analysis.

In other words, the finding comes from a subset selected from the full study population.

This is inherently weaker evidence than:

a prespecified primary endpoint assessed in all participants.

Unlike β-Lactolin, it is therefore premature to treat:

memory retrieval

as MHBA’s best-established benefit.

12. MHBA’s Proposed Mechanism

This might be where this ingredient is really worth looking into.

The proposed pathway is not:

Eaten → Directly cross the blood-brain barrier in large quantities → Stimulate neurons

A more plausible pathway is:

Intestine → Vagus Nerve → Brain

The general mechanism can be written as:

MHBA ↓ intestinal bitter-taste receptors (TAS2R) ↓ enteroendocrine cells ↓ CCK (cholecystokinin) release ↓ vagal afferent signaling ↓ brainstem ↓ locus coeruleus ↓ norepinephrine / noradrenaline ↓ changes in attention, arousal, memory retrieval, and executive control

This chain is currently supported by a series of cell and animal experiments.

13. Step 1: Activation of Bitter Taste Receptors

This step has been studied in considerable detail.

Researchers screened human bitter taste receptors and found that MHBA is recognized by specific bitter taste receptors, including:

TAS2R1

TAS2R8

TAS2R10

When these receptors were inhibited in enteroendocrine cells, the MHBA-induced:

cellular response:

Ca²⁺ response

and:

CCK production

were both partially suppressed.

So instead of simply saying:

“Because hops are bitter, they stimulate the brain.”

Instead, there is genuine:

receptor-level evidence.

14. Step 2: CCK

After MHBA stimulates enteroendocrine cells, it can increase:

cholecystokinin

CCK

the gut hormone cholecystokinin

release.

Animal studies further found that blocking:

CCK1 receptor

blocked part of MHBA’s effects on autonomic nerves and brown adipose tissue.

After cutting the subdiaphragmatic vagus nerve, the related neurological effects are also significantly affected.

Therefore:

MHBA → CCK → vagus

The evidence for this portion of the proposed mechanism is fairly strong.

15. Step 3: Norepinephrine

This is also the biggest difference between MHBA and β-Lactolin.

In experiments on mice:

MHBA can increase:

hippocampal norepinephrine

hippocampal norepinephrine

and associated neurotransmitter release.

At the same time, it improved:

spatial working memory

object recognition memory

and other memory tasks.

After vagotomy:

The memory benefit was greatly reduced.

This finding is important.

This suggests that the effect may not come from:

MHBA directly stimulates the hippocampus.

A more plausible explanation is:

Peripheral gastrointestinal tract stimulation → vagus nerve → central norepinephrine system.

16. Why Might Norepinephrine Improve Attention?

This makes perfect neuroscientific sense.

In the brainstem:

locus coeruleus

LC

the locus coeruleus

It is one of the brain's main sources of norepinephrine.

The LC-NE system is closely involved in:

attentional selection, vigilance, task switching, interference suppression, information prioritization, and memory retrieval.

Human studies show changes in:

Stroop ↑ SDMT ↑ verbal fluency ↑

Animal studies show changes in:

norepinephrine ↑

These findings are mechanistically consistent with one another.

However, it must be particularly emphasized here:

Human studies have not directly demonstrated:

Taking 35 mg MHBA → Significant increase in locus coeruleus NE → hence SDMT elevation.

At present, the complete causal chain is mainly animal data.

17. Is There Human Evidence of an Effect on Vagal Activity?

A valuable small experiment was published in 2023.

Study design:

randomized + double-blind + placebo-controlled + crossover

Participants:

34 participants

Age:

30–64 years

Each participant received both MHBA and placebo on separate occasions, completed cognitive tasks, and underwent:

Heart Rate Variability

HRV

monitoring to assess autonomic activity.

18. Autonomic Findings

Compared to placebo, during cognitive tasks after taking MHBA:

HF power

increased by:

+322.2 ms²

95% CI:

28.0–616.4

p = 0.033

And the total power:

+630.6 ms²

95% CI:

87.0–1174.2

p = 0.025

HF-HRV is often associated with:

parasympathetic / vagal activity

and is commonly used as an indicator of parasympathetic or vagal activity.

So this is currently valuable evidence of human mechanisms:

MHBA may indeed alter autonomic/vagal nerve-related activity in humans.

Reports also indicate improvements in executive function and attention-related tasks after a single ingestion.

19. Does MHBA Work Immediately Like Caffeine?

Not yet.

The crossover experiment suggests that:

a single dose may produce an acute effect,

but the study included:

only 34 participants

And the most consistent, recurring evidence for MHBA in humans still comes from:

35 mg/day × 12 weeks.

Therefore, a more appropriate judgment is:

There is a "potential for acute effects"

But not yet:

the well-established acute stimulant effects seen with caffeine.

After taking caffeine, a large number of experiments can steadily observe:

wakefulness / vigilance / reaction time

changes.

The MHBA is far from reaching this level of evidence maturity.

20. What Do Animal Memory Studies Show?

The animal findings are comparatively strong.

In a scopolamine-induced memory impairment model:

MHBA can improve:

spatial working memory

and:

Object recognition memory

Researchers further tested key ingredients in MHBA:

HAH

HAIH

Effects were also observed.

And:

β-adrenergic receptor blockade

weakened the memory benefit.

Plus:

vagotomy

also eliminated or weakened the effect.

So the entire animal evidence chain is quite complete:

MHBA → vagus → norepinephrine → adrenergic receptors → improved memory.

21. Anti-Inflammatory and Antidepressant-Like Mechanisms

In a mouse LPS inflammation model, MHBA also reduced some brain inflammatory responses and reduced so-called:

depression-like behavior

It also increased norepinephrine-related activity.

Another study found that vagotomy:

altered the observed:

behavioral improvements, norepinephrine changes, and neuronal changes.

This indicates that vagal signaling is important to the effect.

This continues to support:

gut–vagus–brain axis

as a central pathway in MHBA’s proposed mechanism.

22. Why This Does Not Mean MHBA Treats Depression

This is a common leap in supplement marketing.

In animals:

Improvement of LPS-induced depression-like behavior

does not directly establish:

Depression improvement in humans.

Human studies currently suggest only that:

fatigue and certain anxiety/mood scores

may improve modestly.

It’s not enough to say:

MHBA can treat depression.

23. Can MHBA Prevent Alzheimer’s Disease?

This is especially easy to get confused by promotional materials.

There is another class of substances in the field of hop research:

iso-α-acids

IAA

These compounds have been studied extensively in mouse models of Alzheimer’s disease, including work on neuroinflammation and cognitive decline.

Although MHBA also has:

positive results in animal models of memory impairment, neuroinflammation, and obesity-related cognitive decline.

However:

There are no long-term randomized trials in humans demonstrating that MHBAs reduce the incidence of Alzheimer's disease.

Nor is there evidence that it can:

delay progression from MCI to dementia.

Claims such as:

"Hops bitter acid prevents dementia"

should therefore be treated with caution.

They often conflate:

Animal evidence for iso-α-acid

with:

Human mild attention study of MHBA.

The two are not the same thing.

24. A Newer Study in Parkinson’s Disease with Cognitive Decline

Japan’s jRCT registry lists a randomized, double-blind MHBA study in people with Parkinson's disease and mild cognitive decline.

The registered dose was:

MHBA 35 mg/day

with a placebo comparison; the registered study is listed as completed.

However, as of August 9, 2026, no peer-reviewed paper providing enough information to assess efficacy reliably was available in the public record.

It is therefore not yet accurate to say:

“MHBAs have been shown to improve cognitive impairment in Parkinson’s patients.”

The appropriate rating remains:

Insufficient evidence.

25. Another Potential Benefit: Reduced Visceral Fat

Outside the cognitive domain, MHBA’s strongest human evidence may actually concern body fat.

A 2016 RCT, larger than the cognitive trials, enrolled:

200 people

Age:

20 to under 65 years

BMI:

25 to under 30

which corresponds to the overweight range.

The study was randomized, double-blind, and placebo-controlled.

Participants consumed daily:

a 350 mL study beverage

containing:

MHBA 35 mg

Duration:

12 weeks.

26. The Trial Measured More Than Body Weight

Primary endpoint used:

CT

Direct measurement:

abdominal fat area

This provides more useful evidence than relying only on:

"The waist circumference is 1 cm less"

a change in waist circumference.

Compared with placebo:

visceral fat area

Visceral fat area

In:

Week 8 and Week 12

decreased significantly.

And:

total abdominal fat area

There was also a significant decrease in week 12.

Body fat percentage also improved between groups.

The final correlation analysis was approximately:

MHBA n=91 and placebo n=87.

27. Why Might One Ingredient Affect Both Cognition and Visceral Fat?

The explanation again centers on the:

gut–brain / autonomic pathway

As outlined above:

MHBA → bitter receptor → CCK → vagus

Along another branch:

CCK and autonomic modulation can also affect:

brown adipose tissue

BAT

brown fat

Animal experiments have found that MHBA can promote sympathetic nerve activity in brown fat through CCK-related signaling; this effect will be significantly inhibited after blocking CCK1 receptor or affecting the vagus nerve pathway.

The proposed pathway can therefore be divided into two branches:

MHBA → Intestinal bitter taste receptor → CCK → Autonomic nervous system

Then:

→ brain → NE → attention/cognition

Or:

→ Sympathetic nerve/BAT → Energy metabolism → Body fat

It has not been established that this mechanism fully explains the reduction in body fat observed in humans.

28. The Studied Dose Is Remarkably Consistent

As with β-Lactolin’s:

1.6 mg/day

studied dose,

the dose used across MHBA trials is remarkably consistent:

35 mg/day

Two major long-term cognitive studies:

35 mg/day

Body fat research:

35 mg/day

Follow-up clinical studies in Japan:

Also mainly around:

35 mg/day.

When evaluating Japanese products:

Don't just look at:

a generic “matured hops” claim.

The key question is whether:

the product supplies about 35 mg of matured hop bitter acids per day.

29. Can Beer Provide an Equivalent Dose?

No.

MHBA is a specific mixture of oxidation and maturation products derived from hop bitter acids. Commercial products use processed, standardized matured-hop extracts, and MHBA requires dedicated analytical methods for quantification. Ordinary beer derives much of its bitterness from iso-α-acids instead.

Therefore:

Beer should not be used as a substitute for standardized MHBA.

These studies do not support the claim that:

Drinking more beer is good for your brain.

Alcohol itself is another matter entirely.

30. Safety

Currently:

35 mg/day × 12 weeks

The available human safety data are generally reassuring.

For example, in the 200 body fat RCT:

The study found no adverse events related to the experimental beverages and no clinically significant circulatory, blood, or urinary abnormalities.

Therefore at the study dose:

Short- to medium-term safety

This can be seen as an advantage for MHBA.

However:

The 12-week safety cannot be extended directly to:

absolute safety over 20 years of use.

Data of this scale and duration do not currently exist.

31. The Main Limitation of the Evidence

Almost identical to β-Lactolin:

Too Much of the Research Comes from the Same Industry Network

For example, the first 60-person cognitive RCT:

Several of the five authors were affiliated with:

Kirin Holdings

The remainder were from clinical institutions and Keio University.

The industry connection was even clearer in the 200-person body-fat trial:

A large number of authors come directly from:

Kirin Company

In other words, much of the current work on:

Chemical analysis → Animal mechanism → CCK research → Vagus nerve research → Human cognition → Body fat research

comes from Kirin and its partner institutions.

This does not mean that the experiment is invalid.

In particular randomized, double-blind, placebo-controlled designs are truly valuable.

However:

There is a lack of large independent research groups replicating the results.

This is one of the main reasons not to rate the evidence more highly.

32. Another Limitation: Only Some Outcomes Were Significant

For example, a 60-person study:

Verbal fluency:

p=0.034

Stroop:

p=0.019

And another study of 100 people:

SDMT:

p=0.045.

This does not mean that:

every cognitive test improved across the board.

So the most rigorous conclusion should be:

“Signs of improvement emerged on different measures of attention/executive function across multiple RCTs.”

instead of:

“MHBA has been shown to improve cognition across the board.”

These two statements are very different.

33. How Large Is the Actual Effect?

This is also a weakness of the current data.

For β-Lactolin, pooled analyses at least provide estimates such as:

cued recall g≈0.33

This is a relatively easy-to-understand effect size.

MHBA does not yet have a sufficiently reliable:

large, independent meta-analysis

that can quantify:

the average improvement in attention, standardized effect size, or percentage change in reaction time.

The present evidence answers one question better than another:

“Is there an effect?”

The current answer is:

Probably.

But:

"How big is the effect?"

It's still vague now.

Judging from the existing human results, its actual magnitude is more likely to be:

A small improvement, not a pronounced cognitive enhancement.

This is a judgment made based on the trial size, endpoint distribution and p value, rather than a unified effect size directly given by a certain paper.

34. Overall Evidence Ratings for MHBA

For outcomes most relevant to:

memory, concentration, and prolonged work or study

The available evidence can be scored as follows:

These scores are based on a comprehensive assessment of the quality of existing research and are not official ratings.

35. Direct Comparison with β-Lactolin

The comparison highlights different strengths.

If the main question is:

"Which one is better for memorizing things?"

The available evidence favors:

β-Lactolin.

In particular:

Its stronger signals involve retrieving learned information, associative memory, and recall prompted by cues.

If the question is instead:

“Which one is better for attention and information processing at work?”

The available evidence favors:

MHBA.

In particular:

Its stronger signals involve handling multiple streams of information, suppressing interference, visual search, divided attention, and executive control.

Overall Assessment

Matured hop bitter acids are not merely a marketing invention.

It currently has:

Defined chemical composition → oxidized α/β-acid derivatives

Receptor mechanism → TAS2R1/8/10

Intestinal hormone mechanism → CCK

Neural pathway → vagus nerve

Neurotransmitter pathway → norepinephrine

Animal behavioral evidence → memory/cognition

Human autonomic evidence → HRV

Two randomized, double-blind cognitive RCTs → attention, executive function, and some memory outcomes

It also has a larger:

200-person body-fat RCT → CT measurement of visceral fat.

Among functional-food ingredients marketed in Japan for cognition, memory, or attention, MHBA therefore has a moderately strong scientific foundation.

The limitations are equally clear:

Samples remain small, positive findings are confined to selected tests, and many p-values sit close to the significance threshold. Much of the key evidence also comes from Kirin and its research partners, with too little independent replication.

The evidence does not justify saying:

“MHBA markedly enhances the brain.”

A more accurate conclusion is:

About 35 mg per day for several weeks to 12 weeks may produce small improvements in divided or selective attention, executive control, and some aspects of memory retrieval in middle-aged and older adults. The vagus nerve–norepinephrine pathway provides an interesting mechanistic rationale, but there is no evidence that MHBA treats cognitive impairment or prevents Alzheimer’s disease.